Safety and immunogenicity of a recombina
β
E. Dandolos; A. Roumeliotou-Karayannis; S. C. Richardson; Prof. G. Papaevangelou
π
Article
π
1985
π
John Wiley and Sons
π
English
β 340 KB
A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.